Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rescue of Transgenic Alzheimer's Pathophysiology by Polymeric Cellular Prion Protein Antagonists.
Gunther EC, Smith LM, Kostylev MA, Cox TO, Kaufman AC, Lee S, Folta-Stogniew E, Maynard GD, Um JW, Stagi M, Heiss JK, Stoner A, Noble GP, Takahashi H, Haas LT, Schneekloth JS, Merkel J, Teran C, Naderi ZK, Supattapone S, Strittmatter SM. Gunther EC, et al. Among authors: maynard gd. Cell Rep. 2019 Jan 2;26(1):145-158.e8. doi: 10.1016/j.celrep.2018.12.021. Cell Rep. 2019. PMID: 30605671 Free PMC article.
Soluble Nogo-Receptor-Fc decoy (AXER-204) in patients with chronic cervical spinal cord injury in the USA: a first-in-human and randomised clinical trial.
Maynard G, Kannan R, Liu J, Wang W, Lam TKT, Wang X, Adamson C, Hackett C, Schwab JM, Liu C, Leslie DP, Chen D, Marino R, Zafonte R, Flanders A, Block G, Smith E, Strittmatter SM. Maynard G, et al. Lancet Neurol. 2023 Aug;22(8):672-684. doi: 10.1016/S1474-4422(23)00215-6. Lancet Neurol. 2023. PMID: 37479373 Free PMC article. Clinical Trial.
Rescue of Transgenic Alzheimer's Pathophysiology by Polymeric Cellular Prion Protein Antagonists.
Gunther EC, Smith LM, Kostylev MA, Cox TO, Kaufman AC, Lee S, Folta-Stogniew E, Maynard GD, Um JW, Stagi M, Heiss JK, Stoner A, Noble GP, Takahashi H, Haas LT, Schneekloth JS, Merkel J, Teran C, Naderi ZK, Supattapone S, Strittmatter SM. Gunther EC, et al. Among authors: maynard gd. Cell Rep. 2019 Jan 29;26(5):1368. doi: 10.1016/j.celrep.2019.01.064. Cell Rep. 2019. PMID: 30699361 Free PMC article. No abstract available.
Targeting memory processes with drugs to prevent or cure PTSD.
Cain CK, Maynard GD, Kehne JH. Cain CK, et al. Among authors: maynard gd. Expert Opin Investig Drugs. 2012 Sep;21(9):1323-50. doi: 10.1517/13543784.2012.704020. Epub 2012 Jul 27. Expert Opin Investig Drugs. 2012. PMID: 22834476 Free PMC article. Review.
Discovery of N-(1-ethylpropyl)-[3-methoxy-5-(2-methoxy-4-trifluoromethoxyphenyl)-6-methyl-pyrazin-2-yl]amine 59 (NGD 98-2): an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist.
Hodgetts KJ, Ge P, Yoon T, De Lombaert S, Brodbeck R, Gulianello M, Kieltyka A, Horvath RF, Kehne JH, Krause JE, Maynard GD, Hoffman D, Lee Y, Fung L, Doller D. Hodgetts KJ, et al. Among authors: maynard gd. J Med Chem. 2011 Jun 23;54(12):4187-206. doi: 10.1021/jm200365y. Epub 2011 May 27. J Med Chem. 2011. PMID: 21618986
18 results